Inhaled tobramycin (TOBI)

Inhaled tobramycin was recently approved by the FDA in a 300 mg formulation for inhalation. The new product, manufactured by PathoGenesis Corporation, is referred to as TOBI and is indicated for cystic fibrosis patients with Pseudomonas aeruginosa. The advantage of high dose inhaled tobramycin is a greater concentration of the drug delivered to bacteria in the lung with potentially reduced oto- and nephrotoxicity.